Bicara Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Bicara Therapeutics Inc. on June 9, 2025. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol BCAX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 54,536,218 shares outstanding as of the record date, 47,737,314 shares (approximately 87%) were present or represented at the meeting. Two proposals were voted upon:
- Proposal 1: Election of Directors - Stockholders elected three Class I directors for a three-year term ending in 2028.
- Kiran Mazumdar-Shaw: 30,789,699 votes For; 14,383,613 votes Withheld.
- Jake Simson, Ph. D.: 37,615,042 votes For; 7,558,270 votes Withheld.
- Ryan Cohlhepp, Pharm D.: 44,751,607 votes For; 421,705 votes Withheld.
- Proposal 2: Ratification of KPMG LLP - Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Results: 47,726,238 votes For; 7,816 votes Against; 3,260 votes Abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote.
Investor Verification Checklist
- Verify the high number of votes withheld for director Kiran Mazumdar-Shaw (14,383,613) compared to other nominees.
- Confirm the total share count and attendance percentage (87%) against the definitive proxy statement filed on April 25, 2025.
- Review the Company's upcoming 10-K or 10-Q filings for the financial metrics absent from this 8-K.